Prolific Machines, founded in 2020, is a biotechnology company that specializes in photo molecular biology. It uses a production method similar to an industrial assembly line, allowing the company to develop cost-competitive cell-cultured products.
Its platform leverages bioengineering, AI, and light for controlling cell functions rather than the more commonly used yet hard-to-control molecules. According to the company, this process enables scaled production and efficient biomanufacturing of high-value bioproducts including nutritional proteins, antibodies for disease treatment, and cultivated meat.
Funding and financials
In its latest funding round in June 2024, the company raised USD 54.6 million in Series B funding led by The Ki Tua Fund, with participation from Breakthrough Energy Ventures, SOSV, and others. The funding was earmarked for commercialization efforts and customer acquisitions.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.